记者 黄一帆 3月20日，恒瑞医药（600276.SH）宣布其抗体偶联药物（ADC）注射用瑞康曲妥珠单抗被国家药品监督管理局药品审评中心（以下简称“药审中心”）纳入拟突破性治疗品种公示名单。这也是瑞康曲妥珠单抗第8次纳入上述公示名单。

罗氏作为ADC领域的资深玩家，2013年全球首款用于二线治疗HER2阳性乳腺癌的ADC药物Kadcyla就是出自罗氏之手，上市后不久就取得了巨大的商业化成功，2018年的全球销售额已超过10亿美元，成为罗氏业绩顶梁柱的重磅炸弹药物。

In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall ...

Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE. The row over Kadcyla has lasted three years, and has been one of ...

经查询EvaluatePharma数据库，2023年Kadcyla、Enhertu和爱地希全球销售额合计约为57.23亿美元。 截至目前，注射用瑞康曲妥珠单抗相关项目累计研发投入约 ...

Breast cancer treatment Kadcyla, will remain available to patients after a last-minute deal on its price between NHS England and pharma company Roche. The drug was one of dozens marked for de ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.